23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia

by 23andMe  · Based in United States → — Built by scientists, trusted by millions. Understand your genetic health risks and take steps that could change your future.
Hematology Laboratory Medicine

$99 - $499+
Regulatory Status Disclosed

Overview

The 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia is a direct-to-consumer genetic test designed to report on an individual’s genetic predisposition to developing harmful blood clots. Specifically, it screens for the Factor V Leiden variant in the F5 gene and the Prothrombin G20210A variant in the F2 gene, which are the two most common variants linked to hereditary thrombophilia.

This test is intended for individuals 18 years and older and is most relevant for people of European descent, though these variants are also found in populations with European ancestry, such as African Americans and Hispanics or Latinos. It provides risk estimates for developing a harmful blood clot for the first time but does not diagnose hereditary thrombophilia or any other health conditions. Users are advised to consult with a healthcare professional to discuss their results and overall risk, as lifestyle, environment, and other factors also contribute to the risk of blood clots.

The test is part of 23andMe’s broader Health + Ancestry Service, which offers a range of genetic health risk, carrier status, and wellness reports. Customers provide a saliva sample, which is then analyzed using single nucleotide polymorphism (SNP) genotyping. Results are delivered through a secure online account and can be accessed via a mobile app.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Detection of Factor V Leiden variant (F5 gene)
  • Detection of Prothrombin G20210A variant (F2 gene)
  • Direct-to-consumer saliva sample collection
  • Personalized online genetic health risk reports
  • Access to ancestry reports and DNA relative finder
  • Educational resources for healthcare professionals
  • Optional participation in genetic research

Use Cases

  • Understanding genetic predisposition to harmful blood clots
  • Informing discussions with healthcare professionals about personal health risks
  • Assessing genetic risk factors for family planning
  • Proactive health management and lifestyle considerations
  • Contributing to scientific and medical research

What Physicians Need to Know

Evidence Base
The 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia reports on the Factor V Leiden variant in the F5 gene and the Prothrombin G20210A variant in the F2 gene. These are the two most common and well-understood genetic variants linked to hereditary thrombophilia. The test is most relevant for people of European descent. Testing for these variants is recommended by organizations like ACMG and ACOG under certain circumstances.
Clinical Validation Studies
The 23andMe PGS test has been evaluated by the FDA for accuracy, reliability, and consumer comprehension, receiving a de novo classification in November 2017. The test uses qualitative genotyping to detect specific clinically relevant variants from saliva samples. Studies have shown that the test yields correct results for over 99% of samples, with over 99% reproducibility and repeatability. A study published in Molecular Genetics & Genomic Medicine found that direct-to-consumer testing can lead individuals to engage in discussions with healthcare providers and make behavioral changes. This study looked at how over 2,000 people reacted to the Hereditary Thrombophilia report.
Differential Diagnosis Support
The 23andMe Hereditary Thrombophilia report identifies genetic variants associated with an increased risk for developing harmful blood clots but does not diagnose hereditary thrombophilia or any other health conditions. It provides genetic information that can inform discussions with healthcare professionals, who should base diagnostic or treatment decisions on comprehensive patient information.
Clinical Workflow Integration
The 23andMe service is designed for direct-to-consumer use, with individuals collecting saliva samples at home and accessing results through a secure online account. Customers are encouraged to speak with their healthcare providers or a genetic counselor prior to testing. The reports are intended to provide genetic information that may inform health-related lifestyle decisions and conversations with doctors. 23andMe offers resources for clinicians to help interpret patient results.
Physician Tip

Physicians should understand that the 23andMe Hereditary Thrombophilia report identifies genetic predispositions based on two common variants (Factor V Leiden and Prothrombin G20210A) and is not a diagnostic test. Results should be interpreted in the context of a patient's full medical history, family history, and other risk factors. The test is most relevant for individuals of European descent. Genetic counseling is recommended for patients with positive results to discuss implications, further testing, and management strategies. The report can serve as a starting point for discussions about personalized care and preventative measures.

The 23andMe Personal Genome Service is a direct-to-consumer product. It does not directly integrate with electronic health records (EHR) systems or other clinical decision support platforms. Patients receive their results through a secure online account, which they can then share with their healthcare providers. 23andMe provides resources and information for clinicians to help them understand and interpret patient results.

Details

Category Clinical Decision Support & Reference, Lab & Diagnostics
Pricing $99 - $499+
DeploymentCloud
Mobile App1
Compliance
BAA Available No AI-estimated
HIPAA Compliant No AI-estimated
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Hematology, Laboratory Medicine

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2017-04-06DEN160026 De Novo23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

The 23andMe Hereditary Thrombophilia Genetic Health Risk (GHR) Test analyzes two specific genetic variants: the Factor V Leiden variant in the F5 gene and the Prothrombin G20210A variant in the F2 gene. These are the two most common genetic variants linked to hereditary thrombophilia.
This test does not diagnose hereditary thrombophilia or any other health conditions, nor does it provide an overall risk assessment for developing harmful blood clots. It also does not include all possible genetic variants that may increase the risk of blood clots, and results should not be used to make medical decisions or replace professional medical advice.
The 23andMe Hereditary Thrombophilia GHR Test has received FDA authorization, indicating it has been evaluated for accuracy, reliability, and consumer comprehension. The reports meet FDA requirements, with each variant demonstrating over 99% accuracy and reproducibility under different laboratory conditions.
The 23andMe Hereditary Thrombophilia GHR Test is most relevant for people of European descent, as the variants included are most common and best studied in this population. Testing for genetic variants associated with hereditary thrombophilia is recommended by organizations like ACMG and ACOG under certain circumstances.
While 23andMe uses genotyping to detect specific variants, other companies offer different approaches. For instance, some alternatives like CircleDNA utilize whole exome sequencing, which scans all protein-coding genes and is considered more comprehensive, though often at a higher cost. Other services like AncestryDNA and MyHeritage focus more on ancestry and family history rather than health predispositions.
The Hereditary Thrombophilia GHR Test is included in the 23andMe Health + Ancestry Service, which typically costs $199.

Compare 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia

VS
23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia vs Blue Genes AI-Powered Pharmacogenetics
Clinical Decision Support & Reference Adjacent · 65/100
Tool A, 23andMe, focuses on providing direct-to-consumer genetic health risk information for specific conditions like hereditary thrombophilia, empowering individuals with insights for proactive health discussions. Tool B, Blue…
VS
23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia vs Aima Diagnostics
Clinical Decision Support & Reference Adjacent · 65/100
23andMe's tool focuses on providing direct-to-consumer genetic risk information for hereditary thrombophilia through saliva-based DNA testing. Aima Diagnostics, conversely, offers AI-powered interpretation of a broader range of blood…
VS
23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia vs GenXys TreatGx
Clinical Decision Support & Reference Adjacent · 60/100
23andMe's tool is a direct-to-consumer genetic test providing personal health risk insights for hereditary thrombophilia. GenXys TreatGx, on the other hand, is an AI-enhanced clinical decision support system…
VS
23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia vs Invitae Genetic Testing
Clinical Decision Support & Reference Adjacent · 65/100
23andMe's tool is a direct-to-consumer genetic test specifically for hereditary thrombophilia, focusing on two common genetic variants. Invitae, now part of Labcorp, offers a much broader range of…

Related Tools

Stanford University
Stanford University
Clinical Decision Support & Reference
Stanford Online's "AI in Healthcare" program provides a comprehensive overview of artificial intelligence's applications and implications within the medical field.
RADIN Health
RADIN Health
Clinical Decision Support & Reference
RADINA is an AI-powered platform by RADIN Health designed to optimize radiology workflows, enhance diagnostic accuracy, and streamline reporting.
Med-PaLM 2
Google
Clinical Decision Support & Reference
Med-PaLM 2 is a large language model from Google, fine-tuned for healthcare to provide high-quality answers to medical questions and support clinical decision-making.
Pacmed Critical Discharge
Pacmed
Clinical Decision Support & Reference
Pacmed Critical Discharge is an AI tool that predicts the probability of death or readmission within seven days of ICU discharge, providing explainable insights for physicians.
AiZtech Labs
AiZtech Labs
Clinical Decision Support & Reference
AiZtech Labs provides enterprise-grade AI solutions for healthcare, focusing on operational efficiency, diagnostic accuracy, and patient care workflows for providers and health systems.
Stethophone Pro
Sparrow Acoustics
Cardiology AI
Stethophone Pro transforms smartphones into advanced cardiac screening tools, enabling clinicians to capture, interpret, and visualize heart sounds for early detection of cardiovascular diseases.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-04 | First Added: 2026-04-17

Investors who backed 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.